Endpoints AI Day 2026: AI in Biopharma
The question is no longer whether AI can change biopharma. It already is. Pharma giants are reshaping their workforces, the first AI-designed drugs are making their way through the clinic, and record money is meeting rising doubt about the payoff.
AI Day returns in 2026 for the next question: what changes for the people building the future of medicine?
It brings together leaders across biopharma, academia, the frontier labs and venture capital, hosted by Endpoints senior biopharma correspondent Andrew Dunn. Take part two ways: an exclusive in-person experience in New York City or a free virtual-only program.
Speakers include:
- Anthropic Head of Drug Discovery & Development Research Nathan Frey
- Radical Numerics CEO Eric Nguyen
- Recursion CEO Najat Khan
- New York University professor Kyunghyun Cho
- Schrödinger CEO Ramy Farid
- Dimension Capital managing partner and co-founder Zavain Dar
- Genesis Molecular AI CTO Sergey Edunov
Agenda at a Glance
11:00 AM – 2:00 PM ET: Virtual programming
Join us online for a fast-paced editorial briefing hosted by Endpoints journalists. We’ll dig into what AI is actually upending in biopharma, from stunning progress in designing proteins on the computer to visions of ushering in a new era of personalized medicine.
Afternoon sessions: Hybrid + exclusive in-person only experience
3:00 PM – 4:00 PM ET: Arrival & welcome drinks
4:00 PM – 6:00 PM ET: Editorial sessions
6:00 PM – 8:00 PM ET: Happy hour & networking
The conversation shifts to Manhattan for exclusive, live editorial sessions that bring together the AI and biopharma worlds. Endpoints’ Andrew Dunn will lead candid conversations with those industries’ most influential voices, with topics ranging from pharma’s cultural remaking to managing biosecurity concerns to the future role of the human scientist.
Afternoon programming will be followed by a networking reception with an open bar and heavy hors d’oeuvres.
Hosted by:
